US sales contribute about a third of Sun Pharma’s overall revenue
India’s leading generic player Sun Pharma could take a major hit in its bottomline in consequence of USFDA seizure of drugs and raw materials alleging repeated violations in manufacturing practices in Caraco’s facilities in Detroit.
US marshals, at the request of the FDA, seized drug products manufactured at Caraco’s facilities in Detroit, Farmington Hills, and Wixom on 25th June. The seizure also includes ingredients held at these same facilities, Caraco said in a press statement.
Generic drugs seized by federal authorities could cost Detroit-based Caraco Pharmaceuticals an estimated $15 million to $20 million in lost inventory.
Similar stories from DWS PillScribe:
“While we have not fully determined the impact of this action by the FDA on our financial condition, we believe that it may have a material adverse effect on our near-term operations,” Caraco said in the statement.
Currently, US sales contribute about a third of Sun Pharma’s overall revenue. The revenues from US sales are almost equally divided between the drugs made and sold by Caraco and those made by Sun Pharma and distributed by Caraco.
The US FDA action follows Caraco’s continued failure to meet the FDA’s current Good Manufacturing Practice (cGMP) requirements.
Since January 2009, Caraco has initiated voluntary recalls of drug products to protect the public from potentially defective medications. The recalls involved manufacturing defects, including oversized tablets and possible formulation error.
The FDA’s most recent inspection of Caraco, completed in May 2009, found unresolved violations of cGMP requirements. Today’s seizure is intended to lead to major changes at Caraco’s facilities, an FDA release said.
Through this seizure, the FDA seeks to immediately stop the firm from further distributing drugs until there is assurance that the firm complies with good manufacturing requirements.
Caraco manufactures 33 drugs in multiple strengths.The FDA seizure of Caraco’s drugs may create a shortage of one product, choline magnesium trisalicylate oral tablets, which are commonly used as pain relievers.
Products manufactured by third party companies and sold under the Caraco label won’t be affected by the FDA seizure. Nor will the seizure affect products recently sold into the market by Caraco, the release said.
Caraco sells about 3.6 billion generic tablets in more than 50 products annually to wholesalers, drug distributors and retail giants.
Caraco manufactures a wide variety of drugs, including the popular diabetes medicine metformin and the pain reliever tramadol (see Caraco’s complete list of products below) .
Recently, USFDA initiated a similar action banning Ranbaxy from importing more than 30 generic drugs into the U.S. because of manufacturing violations at two Indian plants. The FDA action considerably dented the near term and long prospects of the company.
In May, the FDA issued a warning letter to generic drug maker Lupin Ltd. related to quality issues at a company facility in India.
Observational letters were also sent to Cipla Ltd.’s plants during routine inspections earlier this year.
For Caraco, the FDA move comes after the company had in November last year received a warning letter from the agency related to quality control issues at its Detroit manufacturing plant.
The company earlier this year voluntarily initiated a recall of some products manufactured in the Detroit facility.
For the fourth quarter ended March 31, Sun Pharma’s consolidated net sales fell 9.8% to 11.34 billion rupees from a year earlier, dragged down by a 67% drop in Caraco’s fourth-quarter sales.
Cetirizine IR Tablets
Choline Magnesium Trisalicylate Tablets
Citalopram HBR Tablets
Fluvoxamine Maleate Tablets
Meperidine HCl C-II Tablets
Metoprolol Tartrate Tablets
Paromomycin Sulfate, USP Capsules
Phentermine HCl Tablets
Ticlopidine HCl Tablets
Tizanidine HCl Tablets
Tramadol HCl Tablets
Tramadol HCl/Acetaminophen Tablets
Zolpidem Tartrate Tablets
1676 errors in 15 Ranbaxy filings: US FDA audit
US FDA warning on Mandideep facility may hit Lupin’s revenue
US FDA finds manufacturing errors in Cipla’s Bangalore plant
Suppliers of API & formulations likely to face heightened US FDA scrutiny